详情描述
Tafamidis, Tafamidis, also known as Fx-1006 or PF-06291826, is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein.
Product information
CAS Number: 594839-88-0
Molecular Weight: 308.12
Formula: C14H7Cl2NO3
Synonym:
Fx-1006A
Vyndaqel
Fx1006A
Fx 1006A
Chemical Name: 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
Smiles: OC(=O)C1=CC2OC(=NC=2C=C1)C1C=C(Cl)C=C(Cl)C=1
InChiKey: TXEIIPDJKFWEEC-UHFFFAOYSA-N
InChi: InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
Products are for research use only. Not for human use.